Have a feature idea you'd love to see implemented?
Let us know!
OMGA Omega Therapeutics Inc
Price (delayed)
$1.45
Market cap
$79.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.42
Enterprise value
$161.07M
Highlights
The revenue has soared by 142% year-on-year and by 28% since the previous quarter
The company's gross profit has surged by 142% YoY and by 28% QoQ
The equity has dropped by 73% year-on-year and by 36% since the previous quarter
Omega Therapeutics's quick ratio has decreased by 46% YoY and by 27% from the previous quarter
Key stats
What are the main financial stats of OMGA
Market
Valuations
Earnings
Shares outstanding
55.15M
Market cap
$79.97M
Enterprise value
$161.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.05
Price to sales (P/S)
12.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.51
Revenue
$6.31M
EBIT
-$77.26M
EBITDA
-$71.18M
Free cash flow
-$66.72M
Per share
Balance sheet
Liquidity
EPS
-$1.42
Free cash flow per share
-$1.21
Book value per share
$0.48
Revenue per share
$0.11
TBVPS
$3.05
Total assets
$168.23M
Total liabilities
$141.96M
Debt
$126.95M
Equity
$26.26M
Working capital
$30.52M
Debt to equity
4.83
Current ratio
2.19
Quick ratio
1.82
Net debt/EBITDA
-1.14
Margins
Efficiency
Dividend
EBITDA margin
-1,127.4%
Gross margin
100%
Net margin
-1,249.5%
Operating margin
-1,277.1%
Return on assets
-40.8%
Return on equity
-156.5%
Return on invested capital
-33.3%
Return on capital employed
-54.1%
Return on sales
-1,223.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OMGA stock price
How has the Omega Therapeutics stock price performed over time
Intraday
8.21%
1 week
39.42%
1 month
9.85%
1 year
-9.38%
YTD
-51.83%
QTD
18.85%
Financial performance
How have Omega Therapeutics's revenue and profit performed over time
Revenue
$6.31M
Gross profit
$6.31M
Operating income
-$80.63M
Net income
-$78.9M
Gross margin
100%
Net margin
-1,249.5%
The revenue has soared by 142% year-on-year and by 28% since the previous quarter
The company's gross profit has surged by 142% YoY and by 28% QoQ
The company's operating margin has surged by 71% YoY and by 34% QoQ
The net margin has surged by 71% year-on-year and by 33% since the previous quarter
Growth
What is Omega Therapeutics's growth rate over time
Valuation
What is Omega Therapeutics stock price valuation
P/E
N/A
P/B
3.05
P/S
12.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.51
The EPS has grown by 36% YoY and by 14% from the previous quarter
The equity has dropped by 73% year-on-year and by 36% since the previous quarter
The stock's price to book (P/B) is 10% less than its last 4 quarters average of 3.4
The revenue has soared by 142% year-on-year and by 28% since the previous quarter
The price to sales (P/S) is 67% less than the last 4 quarters average of 38.3
Efficiency
How efficient is Omega Therapeutics business performance
The ROS has soared by 71% YoY and by 33% from the previous quarter
The ROIC has soared by 67% YoY and by 16% from the previous quarter
OMGA's ROE has plunged by 61% YoY and by 15% from the previous quarter
OMGA's return on assets is up by 36% year-on-year and by 8% since the previous quarter
Dividends
What is OMGA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OMGA.
Financial health
How did Omega Therapeutics financials performed over time
The total assets is 18% greater than the total liabilities
Omega Therapeutics's quick ratio has decreased by 46% YoY and by 27% from the previous quarter
Omega Therapeutics's current ratio has decreased by 41% YoY and by 24% from the previous quarter
The equity has dropped by 73% year-on-year and by 36% since the previous quarter
OMGA's debt to equity has surged by 56% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.